Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2076111

Cn1nc(-c2ccccc2)c(C[P+](c2ccccc2)(c2ccccc2)c2ccccc2)c1Cl.[Cl-]

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.57
TDP1 Q9NUW8 2/20 0.57
ALDH1A1 P00352 1/20 0.53
MAPT P10636 4/20 0.53
GAA P10253 1/20 0.53
LMNA P02545 1/20 0.52
RECQL P46063 2/20 0.50
SMN1; SMN2 Q16637 5/20 0.46
MPO P05164 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.39
EPHA2 P29317 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12775563 0.81 NPSR1 (0.61) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL14191068 0.79 NPSR1 (0.66) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL2076868 0.79 NPSR1 (0.66) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL2077156 0.77 TDP1 (0.64) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL3809599 0.72 NPSR1 (0.58) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL266137 0.70 RECQL (0.58) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL2077714 0.69 NPSR1 (0.51) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL2077392 0.68 NPSR1 (0.49) NPSR1TDP1ALDH1A1MAPTGAA
SCHEMBL2077388 0.68 TDP1 (0.52) NPSR1TDP1ALDH1A1MAPTGAA
Hydrochloric Acid SCHEMBL18110366 0.67 HIF1A (0.39) ALDH1A1LMNASMN1; SMN2KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
US-7659298-B2 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting SANOFI-AVENTIS (FR) 2010-02-09 US disclosed
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
EP-1699454-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2006-09-13 EP disclosed
WO-2005060959-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R NPSR1 8/4885TDP1 4727/4885ALDH1A1 2239/4885
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R NPSR1 8/4885TDP1 4727/4885ALDH1A1 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.